A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Subcutaneously and Intramuscularly Administered TMB-607 in HIV-Negative Volunteers

TaiMed Biologics Inc.1 site in 1 country9 target enrollmentNovember 21, 2016

ConditionsHuman Immunodeficiency Virus

InterventionsPlacebo TMB-607

DrugsTMB-607 Placebo

Overview

Phase: Phase 1
Intervention: Placebo
Conditions: Human Immunodeficiency Virus
Sponsor: TaiMed Biologics Inc.
Enrollment: 9
Locations: 1
Primary Endpoint: TMB 607 plasma concentrations
Status: Terminated
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative volunteers.

Detailed Description

This study uses a sequential dose-escalation design for single dose subcutaneous and intramuscular administrations in HIV-negative volunteers. The study investigates seven TMB-607 dose groups: Cohort 1: 200 mg subcutaneously (Arm A), 500 mg subcutaneously (Arm B) and 1,000 mg subcutaneously (Arm C); Cohort 2: 100 mg intramuscularly (Arm A), 400 mg intramuscularly (Arm B), 800 mg intramuscularly (Arm C) and 1,500 mg intramuscularly (Arm D). Five participants will be enrolled in each dose group, and will be randomly assigned in a 4:1 ratio to receive TMB-607 or placebo in a double-blinded fashion (four participants per group assigned to active TMB-607; one participant per group assigned to placebo). In each group, a single dose injection of TMB-607 or placebo will be administered at Day 0. The first three Day 0 injections administered in each dose group must be given at least 24 hours apart. Subjects will be enrolled sequentially so that a maximum of three subjects in each Cohort is dosed within any 24-hour period. All subjects will be monitored for 24 hours after study drug administration, with vital signs and ECGs checked hourly, and intensive pharmacokinetic samples collected during this period. Study drug will only be administered on Mondays to prevent weekend days from interfering with the daily assessments closest to the time of dosing. Participants will be followed for 10 weeks after receiving study drug.

Registry

clinicaltrials.gov

Start Date

November 21, 2016

End Date

July 22, 2019

Last Updated

5 years ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

TaiMed Biologics Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants must meet all of the following criteria to be included in the study:
•Male or female between 18-55 years of age on the day of screening
•HIV-negative volunteers, willing to undergo HIV testing and counseling, and receive HIV test results
•Normal 12-lead ECG at Screening and on Day 0, including normal sinus rate and rhythm, QTc interval ≤440msec, PR interval ≤200msec, and lack of any evidence of heart block, or left or right bundle branch block
•Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
•In the opinion of the principal investigator or designee, has understood the information provided; written informed consent needs to be given before any study-related procedures are performed
•Agrees to use a barrier form of contraception if engaging in sexual activity at any time throughout the study (males and females) - two reliable forms of barrier contraception diaphragm, Intra Uterine Device (IUD), spermicides or condoms) must be used if participants engage in sexual activity that could result in pregnancy; hormonal contraception (e.g., oral contraceptive pill, injectable or implantable contraceptive) must not be relied upon while in this study; all female participants must be willing to undergo urine pregnancy tests at time points indicated in the Schedule of Events and Procedures
•For females of reproductive potential, negative urine pregnancy test at screening and within 96 hours prior to randomization; female participants of reproductive potential are defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months) or have not undergone surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, salpingectomy, or tubal ligation)

Exclusion Criteria

•Participants having or meeting any of the following conditions or characteristics will be excluded from the study:
•Confirmed HIV-1 or HIV-2 infection
•Currently pregnant or breastfeeding
•Known allergy/sensitivity or any hypersensitivity to components of study drug or its formulation, or known allergy to sulfonamide drugs
•History, or family history of Short of Long QT syndrome, Wolff-Parkinson-White Syndrome, or congenital heart disease
•Family history of sudden cardiac death, or unexplained cardiac death in an otherwise healthy individual between the ages of 1 and 40 years
•History of syncope, palpitations, unexplained dizziness, hypokalemia, heart arrhythmias, or significant cardiac disease
•Major psychiatric illness including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, suicide attempt in the previous 3 years
•Serious illness requiring systemic treatment and/or hospitalization within 21 days prior to randomization
•Receipt of immunomodulatory agents (e.g., interleukins, interferons, cyclosporine, systemic corticosteroids), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 180 days prior to study entry

Time Frame: 10 Weeks Post Injection

Measurements of concentrations of TMB-607 in plasma will be used to determine the concentration-time profile of subcutaneous and intramuscular TMB-607 in all participants. TMB-607 plasma concentrations will be measured by a central lab using high-performance liquid chromatography - mass (HPLC-MS) method validated for the measurement of TMB-607 in human plasma.